Literature DB >> 21775421

Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue.

Kristina A Trujillo1, William C Hines, Keith M Vargas, Anna C Jones, Nancy E Joste, Marco Bisoffi, Jeffrey K Griffith.   

Abstract

Telomerase stabilizes chromosomes by maintaining telomere length, immortalizes mammalian cells, and is expressed in more than 90% of human tumors. However, the expression of human telomerase reverse transcriptase (hTERT) is not restricted to tumor cells. We have previously shown that a subpopulation of human mammary epithelial cells (HMEC) in tumor-adjacent, histologically normal (TAHN) breast tissues expresses hTERT mRNA at levels comparable with levels in breast tumors. In the current study, we first validated a reporter for measuring levels of hTERT promoter activity in early-passage HMECs and then used this reporter to compare hTERT promoter activity in HMECs derived from tumor and paired TAHN tissues 1, 3, and 5 cm from the tumor (TAHN-1, TAHN-3, and TAHN-5, respectively). Cell sorting, quantitative real-time PCR, and microarray analyses showed that the 10% of HMECs with the highest hTERT promoter activity in both tumor and TAHN-1 tissues contain more than 95% of hTERT mRNA and overexpress many genes involved in cell cycle and mitosis. The percentage of HMECs within this subpopulation showing high hTERT promoter activity was significantly reduced or absent in TAHN-3 and TAHN-5 tissues. We conclude that the field of "normal tissue" proximal to the breast tumors contains a population of HMECs similar in hTERT expression levels and in gene expression to the HMECs within the tumor mass and that this population is significantly reduced in tissues more distal to the tumor. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775421      PMCID: PMC3249616          DOI: 10.1158/1541-7786.MCR-10-0424

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  24 in total

Review 1.  Field effect in cancer-an update.

Authors:  Hong Chai; Robert E Brown
Journal:  Ann Clin Lab Sci       Date:  2009       Impact factor: 1.256

2.  Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues.

Authors:  William C Hines; Alexandra M Fajardo; Nancy E Joste; Marco Bisoffi; Jeffrey K Griffith
Journal:  Mol Cancer Res       Date:  2005-09       Impact factor: 5.852

3.  Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.

Authors:  Gong Yang; Daniel G Rosen; Imelda Mercado-Uribe; Justin A Colacino; Gordon B Mills; Robert C Bast; Chenyi Zhou; Jinsong Liu
Journal:  Carcinogenesis       Date:  2006-07-08       Impact factor: 4.944

4.  Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.

Authors:  Christopher M Heaphy; Marco Bisoffi; Colleen A Fordyce; Christina M Haaland; William C Hines; Nancy E Joste; Jeffrey K Griffith
Journal:  Int J Cancer       Date:  2006-07-01       Impact factor: 7.396

5.  Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.

Authors:  Kristina A Trujillo; Christopher M Heaphy; Minh Mai; Keith M Vargas; Anna C Jones; Phung Vo; Kimberly S Butler; Nancy E Joste; Marco Bisoffi; Jeffrey K Griffith
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

6.  Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.

Authors:  J Gu; S Kagawa; M Takakura; S Kyo; M Inoue; J A Roth; B Fang
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

Review 7.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.

Authors:  H F Dvorak
Journal:  N Engl J Med       Date:  1986-12-25       Impact factor: 91.245

8.  Activation of host wound responses in breast cancer microenvironment.

Authors:  Melissa A Troester; Myung Hee Lee; Matthew Carter; Cheng Fan; David W Cowan; Erick Roman Perez; Jason R Pirone; Charles M Perou; D Joseph Jerry; Sallie Smith Schneider
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

Review 9.  Cancer as an overhealing wound: an old hypothesis revisited.

Authors:  Matthias Schäfer; Sabine Werner
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07-16       Impact factor: 94.444

10.  Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients.

Authors:  Anusri Tripathi; Chialin King; Antonio de la Morenas; Victoria Kristina Perry; Bohdana Burke; Gregory A Antoine; Erwin F Hirsch; Maureen Kavanah; Jane Mendez; Michael Stone; Norman P Gerry; Marc E Lenburg; Carol L Rosenberg
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

View more
  8 in total

Review 1.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

2.  Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer.

Authors:  Xiaohong R Yang; Jonine D Figueroa; Stephen M Hewitt; Roni T Falk; Ruth M Pfeiffer; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Montserrat Garcia-Closas; Mark E Sherman
Journal:  Breast Cancer Res Treat       Date:  2012-12-28       Impact factor: 4.872

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

Review 4.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

5.  Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.

Authors:  Jerec W Ricci; Debbie M Lovato; Virginia Severns; Larry A Sklar; Richard S Larson
Journal:  Mol Cancer Ther       Date:  2016-09-26       Impact factor: 6.261

Review 6.  Field cancerization in breast cancer.

Authors:  Emanuela Gadaleta; Graeme J Thorn; Helen Ross-Adams; Louise J Jones; Claude Chelala
Journal:  J Pathol       Date:  2022-05-03       Impact factor: 9.883

7.  β-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro.

Authors:  Roger A Vaughan; Nicholas P Gannon; Randi Garcia-Smith; Yamhilette Licon-Munoz; Miguel A Barberena; Marco Bisoffi; Kristina A Trujillo
Journal:  Mol Cancer       Date:  2014-01-24       Impact factor: 27.401

8.  N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome.

Authors:  Thilde Terkelsen; Vilde D Haakensen; Radka Saldova; Pavel Gromov; Merete Kjaer Hansen; Henning Stöckmann; Ole Christian Lingjaerde; Anne-Lise Børresen-Dale; Elena Papaleo; Åslaug Helland; Pauline M Rudd; Irina Gromova
Journal:  Mol Oncol       Date:  2018-05-14       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.